Shares jump as CryoLife's anti-rejection pulmonary heart valve reaches the US
This article was originally published in Clinica
The first "decellularised" heart valve - a valve made from donated tissue from which the cells have been removed - has been approved for sale in the US market. The share price of the graft's manufacturer, CryoLife, jumped more than 20% on the news - the largest percentage gain that day - rising by $1.38 to reach $8.13.
You may also be interested in...
New guidance from the UK regulator covers distribution and deployment of Pfizer/BioNTech's COVID-19 vaccine, which will be complex because of the temperature storage requirements and the large packs in which the vaccine doses will be delivered.
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
Alpha Source hired a new CEO from Mayline, while Mölnlycke’s CEO comes from CellaVision; Xvivo Perfusion finance chief changed job to become chief operating officer; Shire senior VP now COO at AVITA; and more.